1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijlbpr@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers. So only full paper submission should be [Read More]

Expression of Tumor-Markers and Cytokines in Response to Cichorium endivia L. in Cancerous Mice

El-Sayd E Hafez1, Effat A Badr2, Yasser M Mabrouk2, Mohammed A Seehy2, and Sarah A Aggag2
1. Mubarak City for Scientific Research and Technology Applications, Egypt
2. Department of Genetics, Faculty of Agriculture, Aflaton St., El-Shatby, P.O. Box 21545, Alexandria University, Alexandria, Egypt
Abstract—Most of natural products, such as, medicinal plants and herbs confer protective effects against a wide range of cancers, including colon cancer. Cichorium endivia, L. has been shown to have anti-inflammatory and antioxidant properties. Thirty two male mice were divided into four groups. Group I served as control. Groups 2, 3 and 4 were administered freshly prepared DMH for three weeks, twice per week. Group 3 received the anticancer drug 5 FU for two weeks. Half of this group was sacrificed after 2 weeks while the other half continued until the experiment ended. Group 4 received the plant extract which was divided into 3 sub-groups. Each sub group was administered with a different concentration of the extract (200-400-600 mg/kg bodyweight/ day) for 40 days. Animals were sacrificed; blood was collected and the colons were subjected for investigation. P53 expression was nearly the same in both control and all treated tissues. BCl2 expression decreased in mice treated with 5FU and specifically with Cichorium. TNF-α expression was lower in tissues treated with 5FU compared with the control. Meanwhile, the expression of dose 200 mg/kg.b.wt, was lower than both the control and the 5FU treated tissues. The real time PCR analysis of blood samples showed that the expression of interleukin IL-12 and IL-4 was higher in blood cells treated with plant extract compared with the 5 FU. The two effective doses were 200 and 600 mg/kg.b.wt. In contrast, therapeutic treatments mute the expression of interferon IFN marker. It is thus concluded that, Cichorium endivia, especially dose 200 mg/ kg.b.wt., represents an effective anticancer and immune response drug especially for colon cancer. 

Index Terms—cichorium endivia, tumor-markers, P53, Bcl2, TNF-α, cytokines, IL-12, IL-4, IFN

Cite: El-Sayd E Hafez, Effat A Badr, Yasser M Mabrouk, Mohammed A Seehy, and Sarah A Aggag, "Expression of Tumor-Markers and Cytokines in Response to Cichorium endivia L. in Cancerous Mice," International Journal of Life Sciences Biotechnology and Pharma Research, Vol. 3, No. 4, pp. 33-39, October 2014.
Copyright © 2012-2015 International Journal of Life Sciences Biotechnology and Pharma Research, All Rights Reserved